Idéal Investisseur Connexion Connexion
Français English
CAC 40 : Market open
8 174,18 pts
+0.34%


Last updated : 19/11/2026 - 12h30
🏠 Home   ➤    Stock news

Sanofi shares among the biggest decliners in the CAC 40 despite European green light for VaxRabeo

The pharmaceutical group falls sharply while the Paris index rises. The stock gives up part of its recent strong rebound, after a series of highs. The European authorisation of a new vaccine, announced this Thursday, is not enough to reverse the trend.


Sanofi shares among the biggest decliners in the CAC 40 despite European green light for VaxRabeo

A decline that places Sanofi at the bottom of the Paris index

Sanofi shares fall 2.27% to €84.29 intraday, while the CAC 40 gains 0.34%. Only Capgemini performs worse in the index, placing the stock among the biggest decliners of the CAC 40.

The drop follows a month of strong recovery (+17.17%), so the price remains well above its 20-day moving average (€82.43, a gap of 2.26%). The RSI at 60 remains neutral.

Over the week, the stock loses 2.68%, a modest correction given its monthly rebound, in a market where Wall Street closed mixed the previous day, with the Dow Jones falling by about 1.1%.

A rabies vaccine authorised in Europe, with no visible effect on the share price

The European Commission has granted VaxRabeo its first marketing authorisation, according to the company's announcement on 19 November. The vaccine covers pre-exposure and post-exposure prophylaxis against rabies, for all age groups. The decision follows the positive opinion issued on 17 September by the Committee for Medicinal Products for Human Use of the European Medicines Agency.

According to the consensus of the analysts surveyed, the stock trades at about 9.5 times earnings for the current fiscal year. The share price crossed €87.98 on 16 November, a 250-session high, before pulling back. Resistance at €88.32 remains the nearest technical level above the current price.

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis


Sector Pharmacie et biotechnologies › Pharmacie, vaccins et santé animale


Context

Period
  • Period: 9M 2026
Key reported figures
  • Revenue: 36 550 millions d'euros
  • Quarterly revenue: 36 550 millions d'euros
  • Revenue growth: 13,1 %
  • Net income: 4 979 millions d'euros
  • Free cash flow: 6 993 millions d'euros
  • 12 201 millions d'euros

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
✓ Avant 9h00 ✓ 1000+ inscrits ✓ 100% gratuit
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours sur les valeurs Euronext, chaque matin avant 9h.
tendance · 6 séances
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours